The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...

Recent health news highlights include high costs of weight-loss drugs like Wegovy, Septerna's strong Nasdaq debut, ...

IterumTherapeutics今日宣布，美国FDA已批准其药品Orlynvah（sulopenem etzadroxil & ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum’s new drug application for ...

Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for ...

在2024年10月26日，生物技术公司Allovir, Inc.（股票代码：ALVR.us）盘中股价出现显著波动，迅速拉升5.06%。尽管这一涨幅在整个生物技术行业看来并不算特别突出，但仍引发了广泛的市场关注。本文将深入分析Allovir的股价变动原因，探讨其业务基础、市场前景以及投资者需注意的风险因素，力求为读者呈现一个全面的财经视角。

Highlights,Newell Brands reports a decrease in third-quarter net sales for 2024.,The company focuses on a strategic business ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

Highlights,Iterum Therapeutics receives FDA approval for its new drug, ORLYNVAH.,ORLYNVAH targets uncomplicated urinary tract ...

北京时间2024年10月26日02时33分，Allovir, Inc.（ALVR.us）股票出现波动，股价快速 拉升 5.06%。截至发稿，该股报0.830美元/股，成交量8.9091万股， 换手率 0.08%，振幅8.10%。

Corey Fishman, CEO of Iterum, expressed pride in achieving this FDA approval, emphasizing the drug’s potential to offer new hope for patients dealing with difficult-to-treat infections. The ...